Morusin

Morusin is a prenylated flavonoid isolated from M. australis with various biological activities, such as antitumor, antioxidant, and anti-bacteria property. Morusin could inhibit NF-κB and STAT3 activity.

Product information

CAS Number: 62596-29-6

Molecular Weight: 420.45

Formula: C25H24O6

Synonym:

Mulberrochromene

Chemical Name: 2-(2, 4-dihydroxyphenyl)-5-hydroxy-8, 8-dimethyl-3-(3-methylbut-2-en-1-yl)-4H, 8H-pyrano[2, 3-h]chromen-4-one

Smiles: CC(C)=CCC1=C(OC2=C3C=CC(C)(C)OC3=CC(O)=C2C1=O)C1=CC=C(O)C=C1O

InChiKey: XFFOMNJIDRDDLQ-UHFFFAOYSA-N

InChi: InChI=1S/C25H24O6/c1-13(2)5-7-17-22(29)21-19(28)12-20-16(9-10-25(3,4)31-20)24(21)30-23(17)15-8-6-14(26)11-18(15)27/h5-6,8-12,26-28H,7H2,1-4H3

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : ≥ 100 mg/mL (237.84 mM)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Morusin exhibits a dose- and time-dependent inhibitory effect on murine and human breast cancer cells. IC50 is 9.48 μg/mL for normal mammary epithelial cells (MCF-10A); 2.03 and 1.87 μg/mL for murine breast cancer cells (4 T1 and EMT6); and 2.71 and 3.86 μg/mL for human breast cancer cells (MCF-7 and MDA-MB-231), respectively, the maximal inhibition of cell growth (>80 %) is obtained at 8 μg/mL. The apoptotic cells in morusin treated breast cancer cells are increased significantly in a dose-dependent manner. Morusin significantly inhibits the growth and clonogenicity of human colorectal cancer HT-29 cells. Morusin also inhibits the phosphorylation of IKK-α, IKK-βand IκB-β, increases expression of IκB-α, and suppresses nuclear translocation of NF-κB and its DNA binding activity. Dephosphorylation of NF-κB upstream regulators PI3K, Akt and PDK1 is also displayed. In addition, activation of caspase-8, change of mitochondrial membrane potential, release of cytochrome c and Smac/DIABLO, and activation of caspase-9 and -3 are observed at the early time point. Downregulation in the expression of Ku70 and XIAP is exhibited afterward. Morusin suppresses viability of prostate cancer cells, but little effect in normal human prostate epithelial cells. Morusin also reduces STAT3 activity by inhibiting its phosphorylation, nuclear accumulation, and DNA binding activity. In addition, morusin down-regulated expression of STAT3 target genes encoding Bcl-xL, Bcl-2, Survivin, c-Myc and Cyclin D1. It induces apoptosis in human prostate cancer cells by reducing STAT3 activity.

In Vivo:

Morusin retards the growth of breast cancer significantly. Mean tumor weight of the control mice is 1.14±0.30 g, and those of the mice administrated with 5 and 10 mg/kg of morusin are 0.61±0.23 and 0.41±0.10 g, respectively, tumor inhibitory rates are 46.5 %, and 64.1 %, respectively.

References:

1. Li H, et al. Morusin suppresses breast cancer cell growth in vitro and in vivo through C/EBPβ and PPARγ mediated lipoapoptosis. J Exp Clin Cancer Res. 2015 Nov 4;34:137.
2. Lee JC, et al. Morusin induces apoptosis and suppresses NF-kappaB activity in human colorectal cancer HT-29 cells. Biochem Biophys Res Commun. 2008 Jul 18;372(1):236-42.

Products are for research use only. Not for human use.